

# PROVIDER BULLETIN

## PROVIDER INFORMATION



June 1, 2023

### Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

#### How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center  
Attn: Health Management - Medical Policy  
P.O. Box 10527  
Birmingham, AL 35202  
Fax: 205-220-0878

#### Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-356	Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
MP-561	Transcatheter Mitral Valve Repair and Replacement
MP-755	Digital Health Technologies: Therapeutic Applications
MP-225	Balloon Ostial Dilation
MP-215	Bariatric Surgery

#### Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

<b>Policy #</b>	<b>Policy Title</b>
PH-90697	Syfovre® (pegcetacoplan)
PH-90018	Berinert (C1 Esterase Inhibitor, Human)
PH-90052	Alpha-1-Proteinase Inhibitors: Aralast NP®, Glassia®, Prolastin-C®, Zemaira®
PH-90017	Benlysta® (belimumab)
PH-90693	Briumvi® (ublituximab-xiiy)
PH-90098	Denosumab: Prolia®, Xgeva®
PH-90346	Mepsevii (vestronidase alfa-vjbc)
PH-90503	Reblozyl® (luspatercept-aamt)
PH-90614	Saphnelo® (anifrolumab-fnia)